Summary

  • Dexcom is a leading manufacturer of real-time Continuous Glucose Monitors (rtCGM) in the United States and many parts of the world and provides customers with significant benefits and cost-savings.
  • The company has a track record of industry-leading growth and returns to shareholders; it has a deep connection with its “Warrior” community/consumers that would be hard to replicate in many industries.
  • People with Diabetes were tested on several fronts during COVID-19 as it is one of the leading co-morbidities. These ultra-exigent circumstances resulted in accelerated approval and use of Dexcom’s product, and the results were overwhelmingly successful.
  • The company’s three-pronged growth strategy and R&D and partnerships continually put it at the leading edge of secular trends affecting health care and leave it insulated from many competitive fights as a data provider whose product reduces costs in a very inefficient system.
  • Elevated results match the company’s lofty valuation over time. Management has expanded in areas where it didn’t have an advantage, and we believe it will drive growth above consensus.

COVID-19 was a devastating pandemic that was scary for all of us. It was even more frightening for those suffering from chronic conditions that sig...

Unlock this article with a FREE 30-Day Trial!

An FSI Pro, or FSI Macro subscription is required in order to access this content.

*Free trial available only on a monthly plan

Disclosures (show)

Get invaluable analysis of the market and stocks. Cancel at any time. Start Free Trial

Articles Read 2/2

🎁 Unlock 1 extra article by joining our Community!

You’ve reached your limit of 2 free monthly articles. Please enter your email to unlock 1 more articles.

Already have an account? Sign In

Don't Miss Out
First Month Free